Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 14/20 | 0.50 |
| ▸ | DAGLA | Q9Y4D2 | 8/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | CES1 | P23141 | 2/20 | 0.43 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13505064 | 0.84 | FAAH (0.49) | FAAHDAGLANPC1RAB9ACES1 | |
| SCHEMBL2624377 | 0.80 | NPC1 (0.46) | FAAHDAGLANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3963214 | 0.79 | FAAH (0.54) | FAAHDAGLANPC1RAB9ACES1 | |
| SCHEMBL3959024 | 0.78 | FAAH (0.55) | FAAHDAGLACES1 | |
| SCHEMBL3963205 | 0.78 | SORD (0.49) | FAAHDAGLANPC1RAB9ASHMT2 | |
| SCHEMBL3969330 | 0.77 | FAAH (0.56) | FAAHDAGLACES1 | |
| SCHEMBL3967020 | 0.77 | FAAH (0.56) | FAAHDAGLACES1 | |
| SCHEMBL3961792 | 0.77 | FAAH (0.56) | FAAHDAGLACES1 | |
| SCHEMBL3959306 | 0.77 | FAAH (0.56) | FAAHDAGLACES1 | |
| SCHEMBL3959446 | 0.77 | FAAH (0.56) | FAAHDAGLACES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10383837-B2 | Compositions and methods for modulating metabolic pathways | NUSIRT SCIENCES, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20170312240-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS | NUMETA SCIENCES, INC. | 2017-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170312240-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS | PC, HADHB, ACACB | FAAH 2004/4885DAGLA 2416/4885NPC1 2090/4885 |
| US-10383837-B2 | Compositions and methods for modulating metabolic pathways | PC, HADHB, ACACB | FAAH 2004/4885DAGLA 2416/4885NPC1 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.